Medtronic’s superDimension™ system is the first of its kind to enable Electromagnetic Navigation Bronchoscopy™ (also known as ENB™) procedures. ENB™ procedures provide a minimally invasive approach to accessing difficult-to-reach areas of the lung, which can aid in the diagnosis of lung disease and thereby lead to earlier and personalized treatment, potentially saving lives. Today, leaders in the healthcare industry recognize electromagnetic navigation as a recommended method of obtaining lung tissue biopsies from the peripheral regions.

ACCP Guidelines 3.4.2.1
In patients with peripheral lung lesions difficult to reach with conventional bronchoscopy, electromagnetic navigation guidance is recommended if the equipment and the expertise are available (Grade 1C).

Remark: The procedure can be performed with or without fluoroscopic guidance as long as the guidance has been found complementary to radial probe ultrasound.

Remark: If electromagnetic navigation is not available, TTNA is recommended.

Why did the ACCP make this recommendation?
"Thus EMN [electromagnetic navigation] can be used as a stand-alone procedure without compromising diagnostic yield or increasing risk of pneumothorax." 1

In patients with peripheral lung lesions difficult to reach with conventional bronchoscopy, electromagnetic navigation guidance is recommended if the equipment and the expertise are available (Grade 1C).

Remark: The procedure can be performed with or without fluoroscopic guidance as long as the guidance has been found complementary to radial probe ultrasound.

Remark: If electromagnetic navigation is not available, TTNA is recommended.

Our clinical education team offers you:
- Comprehensive training programs
- Access to regional education network
- Portfolio of education resources
- Support aspects of fellows education
- Reimbursement hotline
- Data-driven, trend-aware websites
- Program implementation tools

Our market development team has tools available to help you:
- Enhance your physician and patient outreach
- Manage the patient care continuum
- Understand appropriate professional and facility coding and measurement
- Implement best practices

EVIDENCE-BASED RECOMMENDATIONS FOR PATIENT-FOCUSED CARE

SIMPLIFIED EXPERIENCES, POWERFUL PARTNERSHIPS

Medtronic provides clinical, market development, technical and sales support along with dynamic industry connections, so physicians can focus on enhancing patient survival and improving the patient experience.

"Specialists and more pulmonologists should know about this technology. And if they’re not using the technology, they should refer their patients to people who are, because for the patient, this is still the best technology out there.”

Carmel Joseph, MD
Interventional Pulmonologist
Doctors Hospital of Augusta

1 May 2013; 143(5_suppl) Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
2 Eberhardt et al. CHEST 2007; 131:1800-1805. Early Study Only
3 Lampr echt, B. et al. Respiratory Medicine 2012 – Overall diagnostic yield 83.9%
4 Wilson, D. Journal of Bronchology 2007 – Lymph nodes 94.3%
5 American Cancer Society, Facts and Figures. 2013
8 Wiener, RS Annals of Internal Medicine Aug 2011; Cox, J, Radiology July 1999
9 Cox, J, Radiology July 1999
10 Tan, BB et al Chest 2003;123(1_suppl):89S-96S
14 Cardillo, G, Ann Thorac Surg 2003; 75(5):1607-11; Discussion

Our clinical education team offers you:
- Comprehensive training programs
- Access to regional education network
- Portfolio of education resources
- Support aspects of fellows education
- Reimbursement hotline
- Data-driven, trend-aware websites
- Program implementation tools

161 Cheshire Lane, Suite 100
Minneapolis, MN 55441-5433
Tel: +1-763-210-4000
Toll Free: +1-800-387-9016
www.medtronic.com
www.superdimension.com

Medtronic, Medtronic with logo, Medtronic logo and Further, Together are U.S. and internationally registered trademarks of Medtronic. ©2015 Medtronic
Medtronic’s superDimension™ system is the first of its kind to enable Electromagnetic Navigation Bronchoscopy™ procedures (also known as ENB™ procedures). ENB™ procedures provide a minimally invasive approach to accessing difficult-to-reach areas of the lung, which can aid in the diagnosis of lung disease and thereby lead to earlier and personalized treatment – potentially saving lives. Today, leaders in the healthcare industry recognize electromagnetic navigation as a recommended method of obtaining lung tissue biopsies from the peripheral regions.

**ACCP Guidelines 3.4.2.1**
In patients with peripheral lung lesions difficult to reach with conventional bronchoscopy, electromagnetic navigation guidance is recommended if the equipment and the expertise are available (Grade 1C).

Remark: The procedure can be performed with or without fluoroscopic guidance and has been found complementary to radial probe ultrasound.

Remark: If electromagnetic navigation is not available, TTNA is recommended.

Why did the ACCP make this recommendation?
"Thus EMN [electromagnetic navigation] can be used as a stand-alone procedure without compromising diagnostic yield or increasing risk of pneumothorax."1

EVIDENCE-BASED RECOMMENDATIONS FOR PATIENT-FOCUSED CARE

Medtronic provides clinical, market development, technical and sales support along with dynamic industry connections, so physicians can focus on enhancing patient survival and improving the patient experience.

**Simplified Experiences, Powerful Partnerships**

Our clinical education team offers you:
- Comprehensive training programs
- Access to regional education network
- Portfolio of education resources
- Support aspects of fellows education
- Reimbursement hotline
- Data-driven, trend-aware websites
- Program implementation tools

Our market development team has tools available to help you:
- Enhance your physician and patient outreach
- Manage the patient care continuum
- Understand appropriate professional and facility coding and measurement
- Implement best practices

Clinically Proven Technology
- More than 35 published peer-reviewed papers
- 2,000+ trained physicians in more than 500+ centers worldwide
- 50,000+ completed procedures
- Pneumothorax rate of 2.3% (similar to conventional bronchoscopy)
- Successful diagnosis of peripheral lesions in 80–89% of cases
- Successful diagnosis of lymph nodes in 94–100% of cases

EVIDENCE-BASED RECOMMENDATIONS FOR PATIENT-FOCUSED CARE

Medtronic’s superDimension™ system is the first of its kind to enable Electromagnetic Navigation Bronchoscopy™ procedures (also known as ENB™ procedures). ENB™ procedures provide a minimally invasive approach to accessing difficult-to-reach areas of the lung, which can aid in the diagnosis of lung disease and thereby lead to earlier and personalized treatment – potentially saving lives. Today, leaders in the healthcare industry recognize electromagnetic navigation as a recommended method of obtaining lung tissue biopsies from the peripheral regions.

**ACCP Guidelines 3.4.2.1**
In patients with peripheral lung lesions difficult to reach with conventional bronchoscopy, electromagnetic navigation guidance is recommended if the equipment and the expertise are available (Grade 1C).

Remark: The procedure can be performed with or without fluoroscopic guidance and has been found complementary to radial probe ultrasound.

Remark: If electromagnetic navigation is not available, TTNA is recommended.

Why did the ACCP make this recommendation?
"Thus EMN [electromagnetic navigation] can be used as a stand-alone procedure without compromising diagnostic yield or increasing risk of pneumothorax."1

EVIDENCE-BASED RECOMMENDATIONS FOR PATIENT-FOCUSED CARE

Medtronic provides clinical, market development, technical and sales support along with dynamic industry connections, so physicians can focus on enhancing patient survival and improving the patient experience.

**Simplified Experiences, Powerful Partnerships**

Our clinical education team offers you:
- Comprehensive training programs
- Access to regional education network
- Portfolio of education resources
- Support aspects of fellows education
- Reimbursement hotline
- Data-driven, trend-aware websites
- Program implementation tools

Our market development team has tools available to help you:
- Enhance your physician and patient outreach
- Manage the patient care continuum
- Understand appropriate professional and facility coding and measurement
- Implement best practices

Clinically Proven Technology
- More than 35 published peer-reviewed papers
- 2,000+ trained physicians in more than 500+ centers worldwide
- 50,000+ completed procedures
- Pneumothorax rate of 2.3% (similar to conventional bronchoscopy)
- Successful diagnosis of peripheral lesions in 80–89% of cases
- Successful diagnosis of lymph nodes in 94–100% of cases

EVIDENCE-BASED RECOMMENDATIONS FOR PATIENT-FOCUSED CARE

Medtronic’s superDimension™ system is the first of its kind to enable Electromagnetic Navigation Bronchoscopy™ procedures (also known as ENB™ procedures). ENB™ procedures provide a minimally invasive approach to accessing difficult-to-reach areas of the lung, which can aid in the diagnosis of lung disease and thereby lead to earlier and personalized treatment – potentially saving lives. Today, leaders in the healthcare industry recognize electromagnetic navigation as a recommended method of obtaining lung tissue biopsies from the peripheral regions.

**ACCP Guidelines 3.4.2.1**
In patients with peripheral lung lesions difficult to reach with conventional bronchoscopy, electromagnetic navigation guidance is recommended if the equipment and the expertise are available (Grade 1C).

Remark: The procedure can be performed with or without fluoroscopic guidance and has been found complementary to radial probe ultrasound.

Remark: If electromagnetic navigation is not available, TTNA is recommended.

Why did the ACCP make this recommendation?
"Thus EMN [electromagnetic navigation] can be used as a stand-alone procedure without compromising diagnostic yield or increasing risk of pneumothorax."1

EVIDENCE-BASED RECOMMENDATIONS FOR PATIENT-FOCUSED CARE

Medtronic provides clinical, market development, technical and sales support along with dynamic industry connections, so physicians can focus on enhancing patient survival and improving the patient experience.

**Simplified Experiences, Powerful Partnerships**

Our clinical education team offers you:
- Comprehensive training programs
- Access to regional education network
- Portfolio of education resources
- Support aspects of fellows education
- Reimbursement hotline
- Data-driven, trend-aware websites
- Program implementation tools

Our market development team has tools available to help you:
- Enhance your physician and patient outreach
- Manage the patient care continuum
- Understand appropriate professional and facility coding and measurement
- Implement best practices

Clinically Proven Technology
- More than 35 published peer-reviewed papers
- 2,000+ trained physicians in more than 500+ centers worldwide
- 50,000+ completed procedures
- Pneumothorax rate of 2.3% (similar to conventional bronchoscopy)
- Successful diagnosis of peripheral lesions in 80–89% of cases
- Successful diagnosis of lymph nodes in 94–100% of cases
THE CHALLENGING LANDSCAPE OF LUNG CARE

Lung cancer is the leading cause of cancer-related deaths in the United States. The number of people with lung disease continues to grow and the challenge of early diagnosis and treatment is more critical than ever. Conventional diagnostic options continue to present a number of real challenges:

- 150,000+ U.S. patients per year present with a Solitary Pulmonary Nodule. Diagnostic yield of peripheral lung lesions of less than 2 cm with traditional bronchoscopy is just 14%. CT Guided Needle Biopsy risks include pneumothorax rates of 15–42%, chest tube insertion rates of 4–17%, and hemoptysis and hemorrhage rates of up to 10%. Diagnostic thoracic surgery is not an option for many compromised patients. Additionally, the non-therapeutic rate is 20–45%.

"I was very relieved there was another option rather than either cutting me open or sticking a needle in there to get the biopsy. I was pleased there was an alternative."

Wayne Bissell

PLANNING

The superDimension™ system planning software uses the patient’s CT scan to create a 3D bronchial tree. The physician uses the software to create pathways to pulmonary targets to be used in the procedure phase.

THE SUPERDIMENSION™ SYSTEM

PROCEDURE

Steerable Guide Catheters

Steerable Guide Catheters allow bronchoscopic access via mouth or nose, provide 360° steerability to hard-to-reach lesions and lymph nodes, and lock in place at lesion for the insertion of diagnostic and therapeutic tools. Are available in a variety of options to best suit the patient and procedure.

Automatic Registration

Automatic Registration matches patient’s anatomy to virtual roadmap.

Real-Time Location

Real-Time Location enables LG tip position to be synchronized in real time.

Compact, User-Friendly Console

Compact, User-Friendly Console moves easily for use in multiple rooms.

Automatic Location Board

Location Board compensates for changes in patient position and orientation during the procedure.

Patient Sensor Triplets

Patient Sensor Triplets (Tracking Sensors) creates an electromagnetic field.

MINIMALLY INVASIVE MULTIPLE APPLICATIONS

RE-THINKING TECHNOLOGY

Stage Lymph Nodes for Diagnosis and Pre-Operative Planning

Place Radiosurgical Markers for Follow-up Radiation Treatment

Locals Re:boradical Markers for Radical Thoracic Procedures

The superDimension™ system may be used to:

Navigate to Peripheral Lung Lesions for Biopsy and Sample Tumor for Targeted Therapy

Lung cancer is the leading cause of cancer-related deaths in the United States. The number of people with lung disease continues to grow and the challenge of early diagnosis and treatment is more critical than ever. Conventional diagnostic options continue to present a number of real challenges:

- 150,000+ U.S. patients per year present with a Solitary Pulmonary Nodule. Diagnostic yield of peripheral lung lesions of less than 2 cm with traditional bronchoscopy is just 14%. CT Guided Needle Biopsy risks include pneumothorax rates of 15–42%, chest tube insertion rates of 4–17%, and hemoptysis and hemorrhage rates of up to 10%. Diagnostic thoracic surgery is not an option for many compromised patients. Additionally, the non-therapeutic rate is 20–45%.

"I was very relieved there was another option rather than either cutting me open or sticking a needle in there to get the biopsy. I was pleased there was an alternative."

Wayne Bissell

"ENB has become a platform technology for further diagnostics and therapeutics in the lung periphery. Guideline status marks a new era of bronchoscopy made possible by ENB."

David S. Wilson, MD, FCCP
Medical Director
The Lung Institute at Columbus Regional Health
THE CHALLENGING LANDSCAPE OF LUNG CARE

Lung cancer is the leading cause of cancer-related deaths in the United States. The number of people with lung disease continues to grow and the challenge of early diagnosis and treatment is more critical than ever. Conventional diagnostic options continue to present a number of real challenges:

- 150,000+ U.S. patients per year present with a Solitary Pulmonary Nodule.
- Diagnostic yield of peripheral lung lesions of less than 2 cm with traditional bronchoscopy is just 1%.1
- CT Guided Needle Biopsy risks include pneumothorax rates of 15–42%,1 chest tube insertion rates of 4–11%,3 hemoptysis and hemorrhage rates of up to 10%.3
- Diagnostic thoracic surgery is not an option for many compromised patients. Additionally, the non-therapeutic rate is 20–45%.11,12,13,14

I was very relieved there was another option rather than either cutting me open or sticking a needle in there to get the biopsy. I was pleased there was an alternative.”

Wayne Bissell
patient

PLANNING

The superDimension™ system planning software uses the patient’s CT scan to create a 3D bronchial tree. The physician uses the software to create pathways to pulmonary targets to be used in the procedure phase.

THE SUPERDIMENSION™ SYSTEM

PROCEDURE

Routinely aligns the patient on the operating bed using the patient position for the procedure.

- Automated Registration
- Patient Sensor Triples
- Compact, User-Friendly Console

Steerable Guide Catheters
- Allow bronchoscopic access via mouth or nose
- Provide 360° steerability to hard-to-reach lesions and lymph nodes
- Lock in place at lesion for the insertion of diagnostic and therapeutic tools

Automatic Registration
- Patient alignment to virtual roadmap

Steerable Guide Catheters
- Allow bronchoscopic access via mouth or nose
- Provide 360° steerability to hard-to-reach lesions and lymph nodes
- Lock in place at lesion for the insertion of diagnostic and therapeutic tools

Real-Time Location
- Enables LG tip position to be synchronized in real time

Compact, User-Friendly Console
- Moves easily for use in multiple rooms

Location Board
- Telemetry for multiple arrays

Location Board Triples
- Telemetry for multiple arrays

Steerable Guide Catheters
- Allow bronchoscopic access via mouth or nose
- Provide 360° steerability to hard-to-reach lesions and lymph nodes
- Lock in place at lesion for the insertion of diagnostic and therapeutic tools

The superDimension™ system may be used to:

- Stage Lymph Nodes for Diagnosis and Pre-Operative Planning
- Place Radiosurgical Markers for Follow-up Radiation Treatment
- Localize Nodules for More Precise Thoracic Procedures
- Navigate to Peripheral Lung Lesions for Biopsy and Sample Tumor Biomarkers to Inform Targeted Therapy

MIMINALLY INVASIVE MULTIPLE APPLICATIONS

THE CHALLENGING LANDSCAPE OF LUNG CARE

THE SUPERDIMENSION™ SYSTEM

PLANNING

THE RE-THINKING TECHNOLOGY

“The superDimension™ system may be used to:

- Stage Lymph Nodes for Diagnosis and Pre-Operative Planning
- Place Radiosurgical Markers for Follow-up Radiation Treatment
- Localize Nodules for More Precise Thoracic Procedures
- Navigate to Peripheral Lung Lesions for Biopsy and Sample Tumor Biomarkers to Inform Targeted Therapy

Lung cancer is the leading cause of cancer-related deaths in the United States. The number of people with lung disease continues to grow and the challenge of early diagnosis and treatment is more critical than ever. Conventional diagnostic options continue to present a number of real challenges:

- 150,000+ U.S. patients per year present with a Solitary Pulmonary Nodule.
- Diagnostic yield of peripheral lung lesions of less than 2 cm with traditional bronchoscopy is just 1%
- CT Guided Needle Biopsy risks include pneumothorax rates of 15–42%, chest tube insertion rates of 4–11%, hemoptysis and hemorrhage rates of up to 10%
- Diagnostic thoracic surgery is not an option for many compromised patients. Additionally, the non-therapeutic rate is 20–45%

I was very relieved there was another option rather than either cutting me open or sticking a needle in there to get the biopsy. I was pleased there was an alternative.”

Wayne Bissell
patient

“This ENB has become a platform technology for further diagnostics and therapeutics in the lung periphery. Guideline status marks a new era of bronchoscopy made possible by ENB.”

David S. Wilson, MD, FCCP
Medical Director
The Lung Institute at Columbus Regional Health

THE CHALLENGING LANDSCAPE OF LUNG CARE

Lung cancer is the leading cause of cancer-related deaths in the United States. The number of people with lung disease continues to grow and the challenge of early diagnosis and treatment is more critical than ever. Conventional diagnostic options continue to present a number of real challenges:

- 150,000+ U.S. patients per year present with a Solitary Pulmonary Nodule.
- Diagnostic yield of peripheral lung lesions of less than 2 cm with traditional bronchoscopy is just 1%
- CT Guided Needle Biopsy risks include pneumothorax rates of 15–42%, chest tube insertion rates of 4–11%, hemoptysis and hemorrhage rates of up to 10%
- Diagnostic thoracic surgery is not an option for many compromised patients. Additionally, the non-therapeutic rate is 20–45%

I was very relieved there was another option rather than either cutting me open or sticking a needle in there to get the biopsy. I was pleased there was an alternative.”

Wayne Bissell
patient

“This ENB has become a platform technology for further diagnostics and therapeutics in the lung periphery. Guideline status marks a new era of bronchoscopy made possible by ENB.”

David S. Wilson, MD, FCCP
Medical Director
The Lung Institute at Columbus Regional Health
THE CHALLENGING LANDSCAPE OF LUNG CARE

Lung cancer is the leading cause of cancer-related deaths in the United States. The number of people with lung disease continues to grow and the challenge of early diagnosis and treatment is more critical than ever. Conventional diagnostic options continue to present a number of real challenges:

- 110,000+ U.S. patients per year present with a Solitary Pulmonary Nodule.
- Diagnostic yield of peripheral lung lesions of less than 2 cm with traditional bronchoscopy is just 14%.
- CT Guided Needle Biopsy risks include pneumothorax rates of 15–42%, chest tube insertion rates of 4–17%, hemoptysis and hemorrhage rates of up to 19%.
- Diagnostic thoracic surgery is not an option for many compromised patients. Additionally, the non-therapeutic rate is 20–45%.

THE SUPERDIMENSION™ SYSTEM

PLANNING

The superDimension™ system planning software uses the patient’s CT scan to create a 3D bronchial tree. The physician uses the software to create pathways to pulmonary targets to be used in the procedure phase.

LOCATION BOARD

Creates an electromagnetic field.

STEERABLE GUIDE CATHETERS

Allow bronchoscopic access via mouth or nose, provide 360° steerability to hard-to-reach lesions and lymph nodes, and lock in place at lesion for the insertion of diagnostic and therapeutic tools. Are available in a variety of options to best suit the patient and procedure.

AUTOMATIC REGISTRATION

Matches patient’s anatomy to virtual roadmap.

REAL-TIME LOCATION

Enables LG tip position to be synchronized in real time.

COMPACT, USER-FRIENDLY CONSOLE

Moves easily for use in multiple rooms.

PROCEDURE

STEREOTACTIC GUIDE CATHETERS

Allow bronchoscopic access via mouth or nose, provide 360° steerability to hard-to-reach lesions and lymph nodes, and lock in place at lesion for the insertion of diagnostic and therapeutic tools.

LOCATION BOARD

Location Board (tracking sensors) compensate for changes in patient position and orientation during the procedure.

LOCATION TRIPLETS

Location Board (tracking sensors) compensate for changes in patient position and orientation during the procedure.

MIMINALLY INVASIVE MULTIPLE APPLICATIONS

Navigate to Peripheral Lung Lesions for Biopsy and Lung Tumor Sampling to Inform Targeted Therapy

Stage Lymph Nodes for Diagnosis and Pre-Operative Planning

Place Radiation Markers for Follow-up Radiation Treatment

LOCALIZE NODULES FOR MORE PRECISE THORACIC PROCEDURES

THE CHALLENGING LANDSCAPE OF LUNG CARE

“I was very relieved there was another option rather than either cutting me open or sticking a needle in there to get the biopsy. I was pleased there was an alternative.”

Wayne Bissell, Patient

Lung cancer is the leading cause of cancer-related deaths in the United States. The number of people with lung disease continues to grow and the challenge of early diagnosis and treatment is more critical than ever. Conventional diagnostic options continue to present a number of real challenges:

- 110,000+ U.S. patients per year present with a Solitary Pulmonary Nodule.
- Diagnostic yield of peripheral lung lesions of less than 2 cm with traditional bronchoscopy is just 14%.
- CT Guided Needle Biopsy risks include pneumothorax rates of 15–42%, chest tube insertion rates of 4–17%, hemoptysis and hemorrhage rates of up to 19%.
- Diagnostic thoracic surgery is not an option for many compromised patients. Additionally, the non-therapeutic rate is 20–45%.

THE SUPERDIMENSION™ SYSTEM

PLANNING

The superDimension™ system planning software uses the patient’s CT scan to create a 3D bronchial tree. The physician uses the software to create pathways to pulmonary targets to be used in the procedure phase.

LOCATION BOARD

Creates an electromagnetic field.

STEERABLE GUIDE CATHETERS

Allow bronchoscopic access via mouth or nose, provide 360° steerability to hard-to-reach lesions and lymph nodes, and lock in place at lesion for the insertion of diagnostic and therapeutic tools. Are available in a variety of options to best suit the patient and procedure.

AUTOMATIC REGISTRATION

Matches patient’s anatomy to virtual roadmap.

REAL-TIME LOCATION

Enables LG tip position to be synchronized in real time.

COMPACT, USER-FRIENDLY CONSOLE

Moves easily for use in multiple rooms.

LOCATION BOARD

Location Board (tracking sensors) compensate for changes in patient position and orientation during the procedure.

LOCATION TRIPLETS

Location Board (tracking sensors) compensate for changes in patient position and orientation during the procedure.

MIMINALLY INVASIVE MULTIPLE APPLICATIONS

Navigate to Peripheral Lung Lesions for Biopsy and Lung Tumor Sampling to Inform Targeted Therapy

Stage Lymph Nodes for Diagnosis and Pre-Operative Planning

Place Radiation Markers for Follow-up Radiation Treatment

LOCALIZE NODULES FOR MORE PRECISE THORACIC PROCEDURES

THE CHALLENGING LANDSCAPE OF LUNG CARE

“I was very relieved there was another option rather than either cutting me open or sticking a needle in there to get the biopsy. I was pleased there was an alternative.”

Wayne Bissell, Patient

Lung cancer is the leading cause of cancer-related deaths in the United States. The number of people with lung disease continues to grow and the challenge of early diagnosis and treatment is more critical than ever. Conventional diagnostic options continue to present a number of real challenges:

- 110,000+ U.S. patients per year present with a Solitary Pulmonary Nodule.
- Diagnostic yield of peripheral lung lesions of less than 2 cm with traditional bronchoscopy is just 14%.
- CT Guided Needle Biopsy risks include pneumothorax rates of 15–42%, chest tube insertion rates of 4–17%, hemoptysis and hemorrhage rates of up to 19%.
- Diagnostic thoracic surgery is not an option for many compromised patients. Additionally, the non-therapeutic rate is 20–45%.

THE SUPERDIMENSION™ SYSTEM

PLANNING

The superDimension™ system planning software uses the patient’s CT scan to create a 3D bronchial tree. The physician uses the software to create pathways to pulmonary targets to be used in the procedure phase.

LOCATION BOARD

Creates an electromagnetic field.

STEERABLE GUIDE CATHETERS

Allow bronchoscopic access via mouth or nose, provide 360° steerability to hard-to-reach lesions and lymph nodes, and lock in place at lesion for the insertion of diagnostic and therapeutic tools. Are available in a variety of options to best suit the patient and procedure.

AUTOMATIC REGISTRATION

Matches patient’s anatomy to virtual roadmap.

REAL-TIME LOCATION

Enables LG tip position to be synchronized in real time.

COMPACT, USER-FRIENDLY CONSOLE

Moves easily for use in multiple rooms.

LOCATION BOARD

Location Board (tracking sensors) compensate for changes in patient position and orientation during the procedure.

LOCATION TRIPLETS

Location Board (tracking sensors) compensate for changes in patient position and orientation during the procedure.

MIMINALLY INVASIVE MULTIPLE APPLICATIONS

Navigate to Peripheral Lung Lesions for Biopsy and Lung Tumor Sampling to Inform Targeted Therapy

Stage Lymph Nodes for Diagnosis and Pre-Operative Planning

Place Radiation Markers for Follow-up Radiation Treatment

LOCALIZE NODULES FOR MORE PRECISE THORACIC PROCEDURES

THE CHALLENGING LANDSCAPE OF LUNG CARE

“I was very relieved there was another option rather than either cutting me open or sticking a needle in there to get the biopsy. I was pleased there was an alternative.”

Wayne Bissell, Patient

Lung cancer is the leading cause of cancer-related deaths in the United States. The number of people with lung disease continues to grow and the challenge of early diagnosis and treatment is more critical than ever. Conventional diagnostic options continue to present a number of real challenges:

- 110,000+ U.S. patients per year present with a Solitary Pulmonary Nodule.
- Diagnostic yield of peripheral lung lesions of less than 2 cm with traditional bronchoscopy is just 14%.
- CT Guided Needle Biopsy risks include pneumothorax rates of 15–42%, chest tube insertion rates of 4–17%, hemoptysis and hemorrhage rates of up to 19%.
- Diagnostic thoracic surgery is not an option for many compromised patients. Additionally, the non-therapeutic rate is 20–45%.

THE SUPERDIMENSION™ SYSTEM

PLANNING

The superDimension™ system planning software uses the patient’s CT scan to create a 3D bronchial tree. The physician uses the software to create pathways to pulmonary targets to be used in the procedure phase.

LOCATION BOARD

Creates an electromagnetic field.

STEERABLE GUIDE CATHETERS

Allow bronchoscopic access via mouth or nose, provide 360° steerability to hard-to-reach lesions and lymph nodes, and lock in place at lesion for the insertion of diagnostic and therapeutic tools. Are available in a variety of options to best suit the patient and procedure.

AUTOMATIC REGISTRATION

Matches patient’s anatomy to virtual roadmap.

REAL-TIME LOCATION

Enables LG tip position to be synchronized in real time.

COMPACT, USER-FRIENDLY CONSOLE

Moves easily for use in multiple rooms.

LOCATION BOARD

Location Board (tracking sensors) compensate for changes in patient position and orientation during the procedure.

LOCATION TRIPLETS

Location Board (tracking sensors) compensate for changes in patient position and orientation during the procedure.

MIMINALLY INVASIVE MULTIPLE APPLICATIONS

Navigate to Peripheral Lung Lesions for Biopsy and Lung Tumor Sampling to Inform Targeted Therapy

Stage Lymph Nodes for Diagnosis and Pre-Operative Planning

Place Radiation Markers for Follow-up Radiation Treatment

LOCALIZE NODULES FOR MORE PRECISE THORACIC PROCEDURES

THE CHALLENGING LANDSCAPE OF LUNG CARE

“I was very relieved there was another option rather than either cutting me open or sticking a needle in there to get the biopsy. I was pleased there was an alternative.”

Wayne Bissell, Patient

Lung cancer is the leading cause of cancer-related deaths in the United States. The number of people with lung disease continues to grow and the challenge of early diagnosis and treatment is more critical than ever. Conventional diagnostic options continue to present a number of real challenges:

- 110,000+ U.S. patients per year present with a Solitary Pulmonary Nodule.
- Diagnostic yield of peripheral lung lesions of less than 2 cm with traditional bronchoscopy is just 14%.
- CT Guided Needle Biopsy risks include pneumothorax rates of 15–42%, chest tube insertion rates of 4–17%, hemoptysis and hemorrhage rates of up to 19%.
- Diagnostic thoracic surgery is not an option for many compromised patients. Additionally, the non-therapeutic rate is 20–45%.
Medtronic’s superDimension™ system is the first of its kind to enable Electromagnetic Navigation Bronchoscopy™ procedures (also known as ENB™ procedures). ENB™ procedures provide a minimally invasive approach to accessing difficult-to-reach areas of the lung, which can aid in the diagnosis of lung disease and thereby lead to earlier and personalized treatment – potentially saving lives. Today, leaders in the healthcare industry recognize electromagnetic navigation as a recommended method of obtaining lung tissue biopsies from the peripheral regions.

**Why did the ACCP make this recommendation?**

“The EMN [electromagnetic navigation] can be used as a stand-alone procedure without compromising diagnostic yield or increasing risk of pneumothorax.”

*ACCP Guidelines 3.4.2.1*

In patients with peripheral lung lesions difficult to reach with conventional bronchoscopy, electromagnetic navigation guidance is recommended if the equipment and the expertise are available (Grade 1C).

**Remark:** The procedure can be performed with or without fluoroscopic guidance and it has been found complementary to radial probe ultrasound.

**Remark:** If electromagnetic navigation is not available, TTNA is recommended.

**EVIDENCE-BASED RECOMMENDATIONS FOR PATIENT-FOCUSED CARE**

Medtronic provides clinical, market development, technical and sales support along with dynamic industry connections, so physicians can focus on enhancing patient survival and improving the patient experience.

**SIMPLIFIED EXPERIENCES, POWERFUL PARTNERSHIPS**

Our clinical education team offers you:

- Comprehensive training programs
- Access to regional education network
- Portfolio of education resources
- Support aspects of fellows education
- Reimbursement hotline
- Data-driven, trend-aware websites
- Program implementation tools

Our market development team has tools available to help you:

- Enhance your physician and patient outreach
- Manage the patient care continuum
- Understand appropriate professional and facility coding and measurement
- Implement best practices

“Specialists and more pulmonologists should know about this technology. And if they’re not using the technology, they should refer their patients to people who are, because for the patient, this is still the best technology out there.”

Carmel Joseph, MD

Interventional Pulmonologist

Doctors Hospital of Augusta

---

**Clinically Proven Technology**

- More than 35 published peer-reviewed papers
- 2,000+ trained physicians in more than 500+ centers worldwide
- 50,000+ completed procedures
- Pneumothorax rate of 2.3% (similar to conventional bronchoscopy)
- Successful diagnosis of peripheral lesions in 80-89% of cases
- Successful diagnosis of lymph nodes in 94-100% of cases

---

**Simplified Experiences, Powerful Partnerships**

Medtronic provides clinical, market development, technical and sales support along with dynamic industry connections, so physicians can focus on enhancing patient survival and improving the patient experience.

---

**Our clinical education team offers you:**

- Comprehensive training programs
- Access to regional education network
- Portfolio of education resources
- Support aspects of fellows education
- Reimbursement hotline
- Data-driven, trend-aware websites
- Program implementation tools

---

**Our market development team has tools available to help you:**

- Enhance your physician and patient outreach
- Manage the patient care continuum
- Understand appropriate professional and facility coding and measurement
- Implement best practices

---

**Clinically Proven Technology**

- More than 35 published peer-reviewed papers
- 2,000+ trained physicians in more than 500+ centers worldwide
- 50,000+ completed procedures
- Pneumothorax rate of 2.3% (similar to conventional bronchoscopy)
- Successful diagnosis of peripheral lesions in 80-89% of cases
- Successful diagnosis of lymph nodes in 94-100% of cases

---

**Simplified Experiences, Powerful Partnerships**

Medtronic provides clinical, market development, technical and sales support along with dynamic industry connections, so physicians can focus on enhancing patient survival and improving the patient experience.

---

**Our clinical education team offers you:**

- Comprehensive training programs
- Access to regional education network
- Portfolio of education resources
- Support aspects of fellows education
- Reimbursement hotline
- Data-driven, trend-aware websites
- Program implementation tools

---

**Our market development team has tools available to help you:**

- Enhance your physician and patient outreach
- Manage the patient care continuum
- Understand appropriate professional and facility coding and measurement
- Implement best practices

---

**Clinically Proven Technology**

- More than 35 published peer-reviewed papers
- 2,000+ trained physicians in more than 500+ centers worldwide
- 50,000+ completed procedures
- Pneumothorax rate of 2.3% (similar to conventional bronchoscopy)
- Successful diagnosis of peripheral lesions in 80-89% of cases
- Successful diagnosis of lymph nodes in 94-100% of cases

---

**Simplified Experiences, Powerful Partnerships**

Medtronic provides clinical, market development, technical and sales support along with dynamic industry connections, so physicians can focus on enhancing patient survival and improving the patient experience.

---

**Our clinical education team offers you:**

- Comprehensive training programs
- Access to regional education network
- Portfolio of education resources
- Support aspects of fellows education
- Reimbursement hotline
- Data-driven, trend-aware websites
- Program implementation tools

---

**Our market development team has tools available to help you:**

- Enhance your physician and patient outreach
- Manage the patient care continuum
- Understand appropriate professional and facility coding and measurement
- Implement best practices

---

**Clinically Proven Technology**

- More than 35 published peer-reviewed papers
- 2,000+ trained physicians in more than 500+ centers worldwide
- 50,000+ completed procedures
- Pneumothorax rate of 2.3% (similar to conventional bronchoscopy)
- Successful diagnosis of peripheral lesions in 80-89% of cases
- Successful diagnosis of lymph nodes in 94-100% of cases

---

**Simplified Experiences, Powerful Partnerships**

Medtronic provides clinical, market development, technical and sales support along with dynamic industry connections, so physicians can focus on enhancing patient survival and improving the patient experience.

---

**Our clinical education team offers you:**

- Comprehensive training programs
- Access to regional education network
- Portfolio of education resources
- Support aspects of fellows education
- Reimbursement hotline
- Data-driven, trend-aware websites
- Program implementation tools

---

**Our market development team has tools available to help you:**

- Enhance your physician and patient outreach
- Manage the patient care continuum
- Understand appropriate professional and facility coding and measurement
- Implement best practices

---

**Clinically Proven Technology**

- More than 35 published peer-reviewed papers
- 2,000+ trained physicians in more than 500+ centers worldwide
- 50,000+ completed procedures
- Pneumothorax rate of 2.3% (similar to conventional bronchoscopy)
- Successful diagnosis of peripheral lesions in 80-89% of cases
- Successful diagnosis of lymph nodes in 94-100% of cases

---

**Simplified Experiences, Powerful Partnerships**

Medtronic provides clinical, market development, technical and sales support along with dynamic industry connections, so physicians can focus on enhancing patient survival and improving the patient experience.

---

**Our clinical education team offers you:**

- Comprehensive training programs
- Access to regional education network
- Portfolio of education resources
- Support aspects of fellows education
- Reimbursement hotline
- Data-driven, trend-aware websites
- Program implementation tools

---

**Our market development team has tools available to help you:**

- Enhance your physician and patient outreach
- Manage the patient care continuum
- Understand appropriate professional and facility coding and measurement
- Implement best practices

---

**Clinically Proven Technology**

- More than 35 published peer-reviewed papers
- 2,000+ trained physicians in more than 500+ centers worldwide
- 50,000+ completed procedures
- Pneumothorax rate of 2.3% (similar to conventional bronchoscopy)
- Successful diagnosis of peripheral lesions in 80-89% of cases
- Successful diagnosis of lymph nodes in 94-100% of cases

---

**Simplified Experiences, Powerful Partnerships**

Medtronic provides clinical, market development, technical and sales support along with dynamic industry connections, so physicians can focus on enhancing patient survival and improving the patient experience.

---

**Our clinical education team offers you:**

- Comprehensive training programs
- Access to regional education network
- Portfolio of education resources
- Support aspects of fellows education
- Reimbursement hotline
- Data-driven, trend-aware websites
- Program implementation tools

---

**Our market development team has tools available to help you:**

- Enhance your physician and patient outreach
- Manage the patient care continuum
- Understand appropriate professional and facility coding and measurement
- Implement best practices

---

**Clinically Proven Technology**

- More than 35 published peer-reviewed papers
- 2,000+ trained physicians in more than 500+ centers worldwide
- 50,000+ completed procedures
- Pneumothorax rate of 2.3% (similar to conventional bronchoscopy)
- Successful diagnosis of peripheral lesions in 80-89% of cases
- Successful diagnosis of lymph nodes in 94-100% of cases

---

**Simplified Experiences, Powerful Partnerships**

Medtronic provides clinical, market development, technical and sales support along with dynamic industry connections, so physicians can focus on enhancing patient survival and improving the patient experience.

---

**Our clinical education team offers you:**

- Comprehensive training programs
- Access to regional education network
- Portfolio of education resources
- Support aspects of fellows education
- Reimbursement hotline
- Data-driven, trend-aware websites
- Program implementation tools

---

**Our market development team has tools available to help you:**

- Enhance your physician and patient outreach
- Manage the patient care continuum
- Understand appropriate professional and facility coding and measurement
- Implement best practices

---

**Clinically Proven Technology**

- More than 35 published peer-reviewed papers
- 2,000+ trained physicians in more than 500+ centers worldwide
- 50,000+ completed procedures
- Pneumothorax rate of 2.3% (similar to conventional bronchoscopy)
- Successful diagnosis of peripheral lesions in 80-89% of cases
- Successful diagnosis of lymph nodes in 94-100% of cases

---

**Simplified Experiences, Powerful Partnerships**

Medtronic provides clinical, market development, technical and sales support along with dynamic industry connections, so physicians can focus on enhancing patient survival and improving the patient experience.